Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 13/20 | 0.73 |
| ▸ | RAB9A | P51151 | 13/20 | 0.73 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.73 |
| ▸ | LMNA | P02545 | 5/20 | 0.73 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.71 |
| ▸ | TP53 | P04637 | 2/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.65 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.65 |
| ▸ | PKM | P14618 | 1/20 | 0.65 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.65 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.65 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.65 |
| ▸ | RELA | Q04206 | 1/20 | 0.65 |
| ▸ | MAPT | P10636 | 4/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.63 |
| ▸ | MEN1 | O00255 | 2/20 | 0.63 |
| ▸ | GAA | P10253 | 2/20 | 0.63 |
| ▸ | GFER | P55789 | 2/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.63 |
| ▸ | POLB | P06746 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30605183 | 0.93 | NPC1 (0.69) | NPC1RAB9ASMN1; SMN2LMNAKDM4E | |
| SCHEMBL28895620 | 0.92 | NPC1 (0.66) | NPC1RAB9ASMN1; SMN2LMNAKDM4E | |
| SCHEMBL30020507 | 0.92 | NPC1 (0.66) | NPC1RAB9ASMN1; SMN2LMNAKDM4E | |
| SCHEMBL13972841 | 0.91 | NPC1 (0.67) | NPC1RAB9ASMN1; SMN2LMNAKDM4E | |
| SCHEMBL1374759 | 0.87 | NPC1 (0.71) | NPC1RAB9ASMN1; SMN2LMNAKDM4E | |
| SCHEMBL28895800 | 0.86 | NPC1 (0.60) | NPC1RAB9ASMN1; SMN2LMNAKDM4E | |
| SCHEMBL30021559 | 0.86 | NPC1 (0.60) | NPC1RAB9ASMN1; SMN2LMNAKDM4E | |
| SCHEMBL28895711 | 0.85 | NPC1 (0.58) | NPC1RAB9ASMN1; SMN2LMNAKDM4E | |
| SCHEMBL29644215 | 0.85 | NPC1 (0.58) | NPC1RAB9ASMN1; SMN2LMNAKDM4E | |
| SCHEMBL1057879 | 0.83 | RAB9A (0.57) | NPC1RAB9ASMN1; SMN2LMNAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1603957-B1 | POLYMERISATION AND OLIGOMERISATION CATALYSTS | INEOS SALES UK LTD (GB) | 2015-10-28 | — | — | EP | disclosed |
| EP-1603957-B1 | POLYMERISATION AND OLIGOMERISATION CATALYSTS | INEOS SALES UK LTD (GB) | 2015-10-28 | — | — | EP | disclosed |
| US-7229943-B2 | Polymerisation and oligomerisation catalysts | INNOVENE EUROPE LIMITED (GB) | 2007-06-12 | — | — | US | disclosed |
| US-7229943-B2 | Polymerisation and oligomerisation catalysts | INNOVENE EUROPE LIMITED (GB) | 2007-06-12 | — | — | US | disclosed |
| US-7229943-B2 | Polymerisation and oligomerisation catalysts | INNOVENE EUROPE LIMITED (GB) | 2007-06-12 | — | — | US | disclosed |
| US-20060094588-A1 | Polymerisation and oligomerisation catalysts | BARCLAYS BANK PLC (GB) | 2006-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094588-A1 | Polymerisation and oligomerisation catalysts | CCNA1, AP2M1, AP2A1 | NPC1 2996/4885RAB9A 2668/4885SMN1; SMN2 3757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.